211 related articles for article (PubMed ID: 35806224)
1. Novel Insights into Factor D Inhibition.
Gavriilaki E; Papakonstantinou A; Agrios KA
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806224
[TBL] [Abstract][Full Text] [Related]
2. Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond.
Gavriilaki E; de Latour RP; Risitano AM
Blood; 2022 Jun; 139(25):3571-3582. PubMed ID: 34482398
[TBL] [Abstract][Full Text] [Related]
3. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
Risitano AM
Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
[TBL] [Abstract][Full Text] [Related]
4. Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria.
Risitano AM; Marotta S
Am J Hematol; 2018 Aug; 93(4):564-577. PubMed ID: 29314145
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition.
Kulasekararaj AG; Kuter DJ; Griffin M; Weitz IC; Röth A
Blood Rev; 2023 May; 59():101041. PubMed ID: 36732204
[TBL] [Abstract][Full Text] [Related]
7. Complementopathies and precision medicine.
Gavriilaki E; Brodsky RA
J Clin Invest; 2020 May; 130(5):2152-2163. PubMed ID: 32310222
[TBL] [Abstract][Full Text] [Related]
8. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
Risitano AM; Perna F; Selleri C
Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
[TBL] [Abstract][Full Text] [Related]
9. [Current treatment of paroxysmal nocturnal hemoglobinuria and prospects for new therapeutic agents in the future].
Nishimura JI
Rinsho Ketsueki; 2021; 62(5):378-387. PubMed ID: 34108318
[TBL] [Abstract][Full Text] [Related]
10. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
Schmidt CQ; Harder MJ; Nichols EM; Hebecker M; Anliker M; Höchsmann B; Simmet T; Csincsi ÁI; Uzonyi B; Pappworth IY; Ricklin D; Lambris JD; Schrezenmeier H; Józsi M; Marchbank KJ
Immunobiology; 2016 Apr; 221(4):503-11. PubMed ID: 26792457
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.
Risitano AM; Marotta S
Semin Immunol; 2016 Jun; 28(3):223-40. PubMed ID: 27346521
[TBL] [Abstract][Full Text] [Related]
12. Paroxysmal nocturnal hemoglobinuria: Where we stand.
Panse J
Am J Hematol; 2023 May; 98 Suppl 4():S20-S32. PubMed ID: 36594182
[TBL] [Abstract][Full Text] [Related]
13. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria.
Risitano AM; Kulasekararaj AG; Lee JW; Maciejewski JP; Notaro R; Brodsky R; Huang M; Geffner M; Browett P
Haematologica; 2021 Dec; 106(12):3188-3197. PubMed ID: 33121236
[TBL] [Abstract][Full Text] [Related]
14. Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab.
Macrae FL; Peacock-Young B; Bowman P; Baker SR; Quested S; Linton E; Hillmen P; Griffin M; Munir T; Payne D; McKinley C; Clarke D; Newton DJ; Hill A; Ariëns RAS
Am J Hematol; 2020 Aug; 95(8):944-952. PubMed ID: 32311169
[TBL] [Abstract][Full Text] [Related]
15. Halting targeted and collateral damage to red blood cells by the complement system.
Jalink M; de Boer ECW; Evers D; Havinga MQ; Vos JMI; Zeerleder S; de Haas M; Jongerius I
Semin Immunopathol; 2021 Dec; 43(6):799-816. PubMed ID: 34191092
[TBL] [Abstract][Full Text] [Related]
16. Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs.
Girmenia C; Barcellini W; Bianchi P; Di Bona E; Iori AP; Notaro R; Sica S; Zanella A; De Vivo A; Barosi G; Risitano A;
Blood Rev; 2023 Mar; 58():101013. PubMed ID: 36117056
[TBL] [Abstract][Full Text] [Related]
17. Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress.
Peffault de Latour R; Hosokawa K; Risitano AM
Semin Hematol; 2022 Jan; 59(1):38-46. PubMed ID: 35491057
[TBL] [Abstract][Full Text] [Related]
18. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Rother RP; Rollins SA; Mojcik CF; Brodsky RA; Bell L
Nat Biotechnol; 2007 Nov; 25(11):1256-64. PubMed ID: 17989688
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics of 512 eculizumab-naive paroxysmal nocturnal hemoglobinuria patients in China: a single-center observational study.
Du Y; Yang Y; Yang C; Chen M; Han B
Hematology; 2022 Dec; 27(1):113-121. PubMed ID: 35068377
[TBL] [Abstract][Full Text] [Related]
20. Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria.
Frieri C; Peffault de Latour R; Sicre De Fontbrune F
Expert Opin Emerg Drugs; 2022 Mar; 27(1):33-43. PubMed ID: 35078384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
